Skip to main content
. Author manuscript; available in PMC: 2021 Sep 1.
Published in final edited form as: Acta Obstet Gynecol Scand. 2020 Apr 9;99(9):1181–1190. doi: 10.1111/aogs.13846

TABLE 4.

Cut-off at 37 weeks. Crude results. Differences between early onset preeclampsia (EOP) and late onset preeclampsia (LOP): EOP: n = 1047 (60.3%); LOP, n = 689 (39.7%). Multiparae with preeclampsia: EOP, n = 578 (64.3%); LOP, n = 321 (35.7%)

Nonsignificant results
Left numbers EOP n = 466
Right numbers LOP n = 1270
P value Significant results
EOP vs LOP
OR [95% CI]
Underlined: difference with cut-off at 34 weeks
P value
Adolescents (<18 y) 3.2% vs 3.8% OR 0.89 .48 Mother age (y, SD) 29.3 vs 28.3 .002
Grand multiparae (5+) 10.4% vs 9.1% OR 1.15 .38 Primigravidity 32.0% vs 39.9% 0.71 [0.58-0.87] .001
BMI ≥25 kg/m2 53.4% vs 53.9% OR 0.98 .46 Chronic hypertension 11.8% vs 7.8% 1.58 [1.13-2.2] .007
Preexisting diabetes 4.2% vs 4.6% OR 0.91 .69 Pre-pregnancy/booking BMI 26.6 vs 27.3 Kg/m2 .03
Coagulopathyb 0.8% vs 0.4% OR 1.98 .29
Smoking 9.4% vs 8.3% OR 1.14 .44
Antecedent 31.5% vs 29.7% OR 1.09 .53
miscarriage
Antecedent abortion 25.4% vs 22.5% OR 1.18 .26
Antecedent thyroid diseasea 2.4% vs 1.3% OR 1.8 .11
Antecedent renal Disease 1.4% vs 0.7% OR 1.8 .23
Allergy/asthma 7.3% vs 6.7% OR 1.11 .32
35 y+ 26.2% vs 22.2% OR 1.24 .06
Medically induced 2.1% vs 1.0% OR 2.1 .08
BMI ≥30 kg/m2 27.4% vs 31.5% OR 0.82 .07
Differences from cut-off at 34 week’s gestation
Items becoming NON significant Items becoming SIGNIFICANT
Antecedent 12.6% vs 9.9% 1.31 .16 Gestation (mean, 2.9 vs 2.6 .006
preeclampsia SD)
Antecedent perinatal 11.8% vs 9.4% 0.77 .21 Parity (mean, SD 1.28 vs 1.10 .02
deaths
Gestational diabetes 15.5% vs 13.9% 1.13 .38 Primiparity 44.8% vs OR 0.71 .001
53.4%
Single mother 35.3% vs 40.1% OR 0.82 .04
Years of schooling ≥10 53.5% vs 58.34% OR 0.82 .05
a

Thyroid diseases: goiter, hypo/hyperthyroidy, thyroidectomy, thyroid node, thyroiditis.

b

“Coagulopathies”: antiphospholipid syndrome, protein C/protein S deficit, factor 5, Leyden or other coagulation factors.